"Imeglimin: Pioneering a Diabetes Revolution with Unprecedented Safety – A Groundbreaking Breakthrough, Unveiling Untapped Potential and Zero Cytotoxicity in Colon Cancer Cells" Cytotoxic activity of Imeglimin against colon cancer cell line.

Abstract

Background: Colon cancer remains a significant global health concern, necessitating the exploration of novel therapeutic approaches. Imeglimin, a promising candidate, which has demonstrated potential antioxidant property and have reduced much oxidative stress in diabetic patients, hence it protects the healthy host cells. This study focuses on evaluating its impact on colon cancer cell viability for assessing its anti-proliferative effect on cellular metabolic activity.

Materials and Methods: Cell Culture: Colon cancer cells (HCT-116) were cultured in appropriate media under standard conditions. Imeglimin Treatment: Cells were treated with varying concentrations of imeglimin for a specified duration. MTT Assay: After treatment, cell viability was assessed using the MTT assay. The MTT reagent was added, and the formazan crystals formed were solubilized before measuring absorbance.

Results: Preliminary results indicate a concentration-dependent decrease in cell viability following imeglimin treatment.

Conclusion: In conclusion, our study provides preliminary evidence of NIL anti-proliferative effects of imeglimin on colon cancer cells, as evidenced by the MTT assay results.